GMAB Stock Price and Chart — NASDAQ:GMAB — TradingView

About Genmab A/S

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Check out other big names from the same industry as GMAB.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy